FIELD: medicine.
SUBSTANCE: invention refers to experimental medicine and may be used for treating tuberculosis infection experimentally. Method includes intravenous administration of a preparation of colloidal silver protargol with micelle size from 10 nm to 600 nm at dose of 1 mg/kg, then 120–240 min later, isoniazid 25 mg/kg is administered. Protargol is administered every 48 hours with underlying isoniazid therapy.
EFFECT: method allows to increase the bioavailability of specific anti-infectious preparations due to the sequential use of the colloidal silver preparation protargol, providing the destruction of the cytoplasmic membrane of the macrophage, and further effect of specific anti-infectious agent on infectious agent.
1 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF SELECTIVE DESTRUCTION OF MACROPHAGES IN CELL SUSPENSION AND WHOLE ORGANISM USING COLLOIDAL SILVER PREPARATIONS - PROTARGOL AND COLLARGOL | 2022 |
|
RU2811772C2 |
| METHOD FOR USING GRANULOMA-FORMING PREPARATIONS WITH A PRIMING ACTION ON CYTOTOXIC MACROPHAGE ACTIVITY TO ENHANCE THE BARRIER-FILTRATION FUNCTION OF LYMPH NODES WITH RESPECT TO MALIGNANT TUMOUR CELLS | 2024 |
|
RU2841520C2 |
| SUBSTANCE SHOWING ANTIHYPOXIC ACTIVITY | 1994 |
|
RU2094056C1 |
| METHOD FOR TREATING PULMONARY TUBERCULOSIS AT PREDOMINANTLY PRODUCTIVE TYPE OF TISSUE REACTION | 2000 |
|
RU2204409C2 |
| COFORMULATED ANTITUBERCULOUS DRUG | 2009 |
|
RU2430724C2 |
| METHOD FOR TREATING ACUTE MILIARY PULMONARY TUBERCULOSIS | 1999 |
|
RU2188034C2 |
| RECOMBINANT INFLUENZA VIRUS STRAINS EXPRESSING MYCOBACTERIAL PROTECTIVE ESAT-6 ANTIGEN AND USES THEREOF IN TUBERCULOSIS TREATMENT AND PROPHYLAXIS | 2005 |
|
RU2318872C2 |
| COMPOSITION FOR TREATMENT OF PULMONARY INFECTION | 2001 |
|
RU2185818C1 |
| METHOD FOR TREATMENT OF PULMONARY TUBERCULOSIS | 2001 |
|
RU2229892C2 |
| AGENT WITH COMBINED NORMALIZING EFFECT ON IMMUNE AND DIGESTIVE BODY SYSTEMS | 2015 |
|
RU2611377C2 |
